<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03580590</url>
  </required_header>
  <id_info>
    <org_study_id>Oral diltiazem in FESS</org_study_id>
    <nct_id>NCT03580590</nct_id>
  </id_info>
  <brief_title>Efficacy of Oral Diltiazem on the Intraoperative Bleeding in Functional Endoscopic Sinus Surgery</brief_title>
  <official_title>Efficacy of Oral Diltiazem Versus Combination of Oral Diltiazem With Intravenous Tranexamic Acid on the Intraoperative Bleeding in Functional Endoscopic Sinus Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  The primary endpoint is the effect of the addition of oral Diltiazem and Tranexamic Acid
           to general anesthesia aided reduction in blood loss during functional endoscopic sinus
           surgery (FESS).

        -  The secondary endpoint is surgeon's assessment of the surgical field and hemodynamics.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Functional endoscopic sinus surgery (FESS) is a minimally invasive technique used to restore
      sinus ventilation and function in patients with recurrent acute or chronic infective
      sinusitis in whom medical therapy has failed.

      Continued bleeding into the surgical field during FESS not only impairs endoscopic vision but
      can lead to complications.

      Controlled hypotension is a technique used to limit intraoperative blood loss to provide the
      best possible field for surgery. The physiological principle which underlies hypotensive
      anesthesia is a natural survival mechanism. When profuse bleeding occurs, the blood pressure
      drops. This drop leads to a reduction or cessation of the bleeding, blood pressure
      stabilization, and recovery. Accordingly, reducing the patient's blood pressure during
      surgery can potentially reduce overall bleeding. Since bleeding in the surgical field is also
      reduced, the surgical field operating conditions are improved In hypotensive anesthesia, the
      patient's baseline mean arterial pressure (MAP) is reduced by 30 %. Consequently, the
      systolic blood pressure values are about 80-90mmHg and the MAP is reduced to 50- 65mmHg.

      Hypotensive anesthesia is considered to be a suitable anesthetic technique for those patients
      who will be undergoing spinal surgery, hip or knee arthroplasty, craniosynostosis, hepatic
      resections, and major maxillofacial operations. Benefits for controlled hypotension for FESS
      include the reduction in blood loss with improved quality of the surgical field.

      Various agent's anesthetic agents, analgesics, and hypotensive drugs, that have been used for
      achieving hypotensive anesthesia:

        1. Volatile Anesthetic Agents. Most anesthetic agents have a hypotensive effect such as
           isoflurane, sevoflurane, and desflurane, high concentrations are required to achieve a
           significant reduction in intraoperative bleeding, and these concentrations may lead to
           hepatic or renal injury.

        2. Propofol. has a potent hypotensive capability, but normal blood pressure will be rapidly
           restored when the propofol infusion is discontinued. Although a short-term propofol
           infusion is safe, a long-term Propofol infusion can cause propofol infusion syndrome in
           children.

        3. Alfentanil, Sufentanil, and Remifentanil. potent synthetic and short-acting opioid
           drugs, Since the recovery times from this type of anesthesia are also short, they are
           widely used for hypotensive anesthesia.

      d.Nitrates. SNP and NTG are two very potent hypotensive agents that are commonly used for
      inducing hypotensive anesthesia. Reflex tachycardia is an unwanted effect which often occurs
      with nitrates administration and can be prevented by a small dose of the beta-adrenoceptor
      antagonist, such as esmolol or propranolol premedication.

      e-beta-Adrenoceptor Antagonists. They effectively used for inducing hypotensive anesthesia
      when administered either as a single hypotensive agent or in combination with SNP.
      Nonselective beta-antagonists, such as labetalol, may cause bronchoconstriction and should be
      avoided in asthmatic patients. The hypotensive action of beta-adrenoceptor antagonists is
      achieved by reducing cardiac output. So, not suitable for the patient with underlying heart
      failure.

      f-Calcium Channel Antagonists. such as nifedipine or nicardipine, are commonly used as
      hypotensive drugs.

      Diltiazem, a calcium channel blocker, blocks the influx of calcium into smooth muscle cells
      and cardiac muscle cells. This causes relaxation of the muscle, thereby causing reduced
      arteriolar tone and fall in blood pressure.

      Tranexamic acid is a synthetic amino acid that inhibits fibrinolysis, which reduces blood
      loss and the need for blood transfusion in total knee arthroplasty, spine surgery, and
      cardiac surgery. It has seen wide application in a variety of surgical procedures since then.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">September 1, 2018</start_date>
  <completion_date type="Anticipated">January 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2019</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Estimated Blood Loss</measure>
    <time_frame>end of operation assessment</time_frame>
    <description>Estimated blood loss in milliliters per hour is calculated by subtracting the volume of total irrigation used during the case from the total amount of fluid in the suction canister at the end of surgery dividing by surgical time in hours.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Boezaart and van der Merwe intraoperative surgical field scale</measure>
    <time_frame>Every 15 minutes for the duration of surgery</time_frame>
    <description>Boezaart Bleeding Scale (BBS) (0 - no bleeding (cadaveric conditions), 1 - Slight bleeding, no suctioning required, 2 - Slight bleeding, occasional suctioning required, 3 - Slight bleeding, frequent suctioning required; bleeding threatens surgical field a few seconds after suction is removed, 4 - Moderate bleeding, frequent suctioning required, and bleeding threatens surgical field directly after suction is removed, 5 - Severe bleeding, constant suctioning required; bleeding appears faster than can be removed by suction; surgical field severely threatened and surgery usually not possible).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of hypotension</measure>
    <time_frame>Hemodynamic parameters as systolic, diastolic and mean arterial blood pressures were recorded before drug intake, before induction, after induction, intraoperative every 5 minutes till the end of surgery, every 15 minutes post operative</time_frame>
    <description>systolic blood pressure values are 80-90mmHg Mean arterial pressure is reduced to 50-65mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>total consumption of propofol</measure>
    <time_frame>end of operation assessment</time_frame>
    <description>The investigators will measure the consumption of propofol intraoperatively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Rate</measure>
    <time_frame>Heart Rate recorded before drug intake, before induction, after induction, intraoperative every 5 minutes till the end of surgery, every 15 minutes postoperative</time_frame>
    <description>heart beats for minutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>End Tidal CO2</measure>
    <time_frame>End Tidal CO2 before induction, after induction, intraoperative every 5 minutes till the end of surgery</time_frame>
    <description>The concentration of carbon dioxide (CO2) in the respiratory gases</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Hypotension on Induction</condition>
  <arm_group>
    <arm_group_label>1st group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 patients will receive 90 mg oral Diltiazem 3 hours pre-operative</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2nd group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 patients will receive 90 mg oral Diltiazem 3 hours pre-operative+ 10 mg/kg IV Tranexamic Acid slow infusion with saline half an hour before the induction of anesthesia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3rd group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>20 patients will receive oral placebo tablet 3 hours pre-operative</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oral Diltiazem</intervention_name>
    <description>Diltiazem, a calcium channel blocker reduced arteriolar tone and fall in blood pressure</description>
    <arm_group_label>1st group</arm_group_label>
    <arm_group_label>2nd group</arm_group_label>
    <other_name>diltiazem</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV Tranexamic Acid</intervention_name>
    <description>Tranexamic acid inhibits fibrinolysis, which reduces blood loss</description>
    <arm_group_label>2nd group</arm_group_label>
    <other_name>capron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>Placebo Oral Tablet</description>
    <arm_group_label>3rd group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        include patients who undergoing elective FESS under general anesthesia and meet these
        criteria:

        - Age from 18 - 60 years old. - ASA grade I - II.

        Exclusion Criteria:

          -  - Patient refusal.

          -  Any contraindication of calcium channel blocker:

               1. AV conduction defects (2nd and 3rd degree AV block).

               2. Sick sinus syndrome.

               3. Wolf-Parkinson-White Syndrome.

               4. History of congestive heart failure.

               5. Patients on long-term ÃŸ-blocker therapy.

          -  Patients with allergy to medication included in the study.

          -  Any contraindication of Tranexamic Acid:

               1. bleeding disorders.

               2. pregnant or breastfeeding mothers.

               3. patient under the influence of anticoagulants.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hamdy Abbas Youssef, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Assiut Univerity</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Moutaz Ismail, MD</last_name>
    <phone>01061844619</phone>
    <phone_ext>+2</phone_ext>
    <email>dr.moetaz89@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amany Hassan Abd ElWahab, PhD</last_name>
    <phone>01004610623</phone>
    <phone_ext>+2</phone_ext>
    <email>amanihassan1976@yahoo.com</email>
  </overall_contact_backup>
  <reference>
    <citation>Aravindan A, Subramanium R, Chhabra A, Datta PK, Rewari V, Sharma SC, Kumar R. Magnesium sulfate or diltiazem as adjuvants to total intravenous anesthesia to reduce blood loss in functional endoscopic sinus surgery. J Clin Anesth. 2016 Nov;34:179-85. doi: 10.1016/j.jclinane.2016.03.068. Epub 2016 May 10.</citation>
    <PMID>27687369</PMID>
  </reference>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>June 12, 2018</study_first_submitted>
  <study_first_submitted_qc>June 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 9, 2018</study_first_posted>
  <last_update_submitted>June 26, 2018</last_update_submitted>
  <last_update_submitted_qc>June 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Moutaz Ragab Ismail Ibrahim</investigator_full_name>
    <investigator_title>M.D</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypotension</mesh_term>
    <mesh_term>Blood Loss, Surgical</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diltiazem</mesh_term>
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

